View all the latest information in
, arranged by trials and clinical studies. Listed below are recently added trial updates.
Coupling germline genetics to interferon-alpha responses in polycythemia vera treatment
Pegylated interferon alfa-2 (PEG-IFN) induces high response rates in many patients with polycythemia vera (PV),...
What is the news about ropeginterferon?
During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to our Steering Committee Chair, Jean-Jacques Kiladjian, Université de Paris, Paris, FR,...
Dysregulation of the bone marrow niche contributes to the pathogenesis of myeloproliferative neoplasms
The bone marrow niche is the local tissue microenvironment that maintains and regulates stem...
Real-world experience with ruxolitinib in myelofibrosis
Ruxolitinib is a Janus kinase (JAK) 1 and JAK 2 inhibitor approved for primary and secondary intermediate-/high-risk myelofibrosis (MF). The...
Phase II results from KRT-232, a first-in-class MDM2 inhibitor, for R/R MF failing JAK inhibitor therapy
Janus kinase (JAK) inhibitors (JAKi) are commonly used in patients with myelofibrosis (MF),...
Why should we target MDM2 with small molecule inhibitor KRT-232 in patients with MF?
During the 25th Congress of the European Hematology Association (EHA), the MPN Hub spoke to Haifa Kathrin Al-Ali,...
Update from MANIFEST phase II study: CPI-0610 + ruxolitinib in patients with myelofibrosis and naïve to JAK inhibitor treatment
Bromodomain and extraterminal domain (BET) proteins are transcriptional...
Trial update of the MANIFEST study of CPI-0610 in patients with myelofibrosis from EHA 2020
MANIFEST (NCT02158858) is a phase II clinical trial of CPI-0610, a small molecule inhibitor of bromodomain...